Skip to main content
Black Health logo Black Health

Clinical interactions & pharmacogenomics

Drug interaction checker

Enter up to four medications. The tool checks every pair against a curated library sourced from FDA labels and CPIC Guidelines, and flags pharmacogenomic differences that matter for Black patients (CYP2C19, CYP2D6, VKORC1, ADRB2).

Your medications

Start typing for suggestions.

Start typing for suggestions.

Start typing for suggestions.

Start typing for suggestions.

Reset

Data sources: FDA labels, CPIC Guidelines, ACC/AHA & ADA guidelines.

Pharmacogenomics for Black patients (1)

  • Warfarin

    VKORC1 / CYP2C9 / CYP4F2

    Warfarin dosing is influenced by three genes: VKORC1 (vitamin K recycling), CYP2C9 (metabolism), CYP4F2 (vitamin K oxidation). African-specific alleles in CYP2C9 (*5, *6, *8, *11) and the rs12777823 variant raise or lower warfarin dose requirements in ways that the original European dosing algorithms do not capture.

    What this means for Black patients: Studies including the COAG trial (Kimmel SE et al. N Engl J Med 2013;369:2283–93) showed pharmacogenomic dosing did not improve outcomes in Black participants using European-derived algorithms. Newer Africa-specific algorithms (Johnson JA et al. Clin Pharmacol Ther 2017) perform better. Discuss genotype testing with your prescriber before or during the first month of therapy.

    Source: CPIC Warfarin Guideline 2017 update. PMID 28198005.

Always talk to your pharmacist. This tool is educational and only surfaces interactions we can cite. Pharmacy software checks every combination in your full medication regimen against continually-updated databases like Lexicomp and Micromedex, use this tool to sharpen the questions you bring to that conversation, not to replace it.

Related resources